Jeff Yass’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.63M Sell
151,200
-6,600
-4% -$148K ﹤0.01% 4576
2026
Q2
$2.81M Buy
157,800
+51,300
+48% +$918K ﹤0.01% 5764
2026
Q1
$1.9M Buy
106,500
+61,700
+138% +$1.35M ﹤0.01% 6294
2025
Q4
$1.21M Buy
44,800
+10,200
+29% +$287K ﹤0.01% 6754
2025
Q3
$1.05M Buy
34,600
+23,900
+223% +$762K ﹤0.01% 7255
2025
Q2
$286K Buy
+10,700
New +$288K ﹤0.01% 10446

Other funds holding CAI

Jeff Yass's CAI Position: Q3 2026 in Review

Jeff Yass increased its Caris Life Sciences (CAI) stake by 80% in Q3 2026, buying an estimated $3.67M and bringing the position to 368,072 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3177.

Jeff Yass first reported a position in CAI in Q3 2025 and has held it in 4 quarters since. 330 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • Jeff Yass held 368,072 shares of Caris Life Sciences worth $11.3M as of Q3 2026.
  • Jeff Yass bought 163,640 Caris Life Sciences shares in Q3 2026, an estimated $3.67M.
  • Caris Life Sciences made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #3177 holding.
  • Jeff Yass first reported a position in Caris Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 330 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.